CD19 and neoplasm: V5-IHC was complemented with either anti-CD3 staining (Figure 4a,c,e) to confirm the identity of CAR-T cells using a proven T cell marker, or with anti-CD19 staining (Figure 4b,d,f) to investigate the co-localization with lymphoma tumor cells.